BMT CTN Protocol 1601 - ECOG-ACRIN EA4151 MCL

A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission.

Below are protocol-related documents, which may be periodically updated.

             Protocol Chair: Timothy Fenske, MD tfenske@mcw.edu

             BMT CTN Chair: Matthew Lunning, MD mlunning@unmc.edu        

             Protocol Coordinator: Colin Burnett cburnett@ecog-acrin.org

             BMT CTN Protocol Coordinator: Amy Foley afoley@nmdp.org

           

For the ECOG-ACRIN EA4151/BMT CTN 1601 study, the BMT CTN is endorsing the study and providing accrual credit. Centers participate via their NCTN group. BMT CTN Centers will receive both NCTN and BMT CTN accrual credits. The protocol may be accessed through the CTSU website: https://www.ctsu.org. For questions about the study and how to participate, contact the ECOG-ACRIN protocol coordinator, Colin Burnett, at cburnett@ecog-acrin.org or 857-504-2900, or the CTSU Help Desk at ctsucontact@westat.com or 1 888 823-5923.